Investigating the efficacy and safety of existing drugs in patients with rare immune diseases

This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.

Related Keywords

Utrecht ,Netherlands ,Amsterdam ,Noord Holland ,Salaar ,Limburg ,Rotterdam ,Zuid Holland ,Holland ,Dutch ,Radboudumc Nijmegen ,Arthritis Research ,University Medical Center Utrecht ,Health Holland ,Zuyderland Medical Center Heerlen ,Medical Center ,Drug Rediscovery ,Rare Immune Mediated Inflammatory Diseases ,Clinical Immunology ,Rare Immune Mediated Inflammatory ,Collaboration Hub ,Drugs ,Anti Inflammatory ,Arthritis ,Efficacy ,Hospital ,Myositis ,Research ,Rheumatoid Arthritis ,Ulcerative Colitis ,